{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T23:02:45Z","timestamp":1771023765103,"version":"3.50.1"},"reference-count":55,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["M\u00e9decine et Maladies Infectieuses"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.medmal.2017.05.002","type":"journal-article","created":{"date-parts":[[2017,6,10]],"date-time":"2017-06-10T12:03:05Z","timestamp":1497096185000},"page":"375-381","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Respiratory infections associated with anti-TNF\u03b1 agents"],"prefix":"10.1016","volume":"47","author":[{"given":"E.","family":"Blanchard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.-E.","family":"Truchetet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Machelart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"S\u00e9neschal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Raherison-Semjen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.medmal.2017.05.002_bib0280","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1517\/14740338.2015.1009036","article-title":"Infection risk associated with anti-TNF-\u03b1 agents: a review","volume":"14","author":"Murdaca","year":"2015","journal-title":"Expert Opin Drug Saf"},{"issue":"9194","key":"10.1016\/j.medmal.2017.05.002_bib0285","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","article-title":"Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group","volume":"354","author":"Maini","year":"1999","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.medmal.2017.05.002_bib0290","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.10697","article-title":"Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial","volume":"48","author":"Weinblatt","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.medmal.2017.05.002_bib0295","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1056\/NEJM199901283400401","article-title":"A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate","volume":"340","author":"Weinblatt","year":"1999","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.medmal.2017.05.002_bib0300","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S1473-3099(03)00545-0","article-title":"Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management","volume":"3","author":"Gardam","year":"2003","journal-title":"Lancet Infect Dis"},{"issue":"9","key":"10.1016\/j.medmal.2017.05.002_bib0305","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1002\/art.10524","article-title":"Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study","volume":"46","author":"Doran","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"19","key":"10.1016\/j.medmal.2017.05.002_bib0310","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.medmal.2017.05.002_bib0315","first-page":"CD008794","article-title":"Adverse effects of biologics: a network meta-analysis and Cochrane overview","author":"Singh","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"10.1016\/j.medmal.2017.05.002_bib0320","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/rheumatology\/keg263","article-title":"Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy","volume":"42","author":"Kroesen","year":"2003","journal-title":"Rheumatol Oxf Engl"},{"issue":"2","key":"10.1016\/j.medmal.2017.05.002_bib0325","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1093\/rheumatology\/kel236","article-title":"Infections during tumour necrosis factor-alpha blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients","volume":"46","author":"Salliot","year":"2007","journal-title":"Rheumatol Oxf Engl"},{"issue":"9990","key":"10.1016\/j.medmal.2017.05.002_bib0330","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S0140-6736(14)61704-9","article-title":"Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis","volume":"386","author":"Singh","year":"2015","journal-title":"Lancet Lond Engl"},{"issue":"9","key":"10.1016\/j.medmal.2017.05.002_bib0335","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1086\/383317","article-title":"Granulomatous infectious diseases associated with tumor necrosis factor antagonists","volume":"38","author":"Wallis","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.medmal.2017.05.002_bib0340","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1002\/art.24632","article-title":"Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry","volume":"60","author":"Tubach","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.medmal.2017.05.002_bib0345","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1002\/art.22808","article-title":"Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies","volume":"56","author":"Dixon","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.medmal.2017.05.002_bib0350","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/rheumatology\/keq242","volume":"50","author":"Galloway","year":"2011","journal-title":"Rheumatol Oxf Engl"},{"issue":"4","key":"10.1016\/j.medmal.2017.05.002_bib0355","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1002\/art.22504","article-title":"Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists","volume":"56","author":"Curtis","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.medmal.2017.05.002_bib0360","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1136\/ard.2006.062760","article-title":"Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists","volume":"66","author":"Askling","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.medmal.2017.05.002_bib0365","series-title":"Vaccination des personnes immunod\u00e9prim\u00e9es ou aspl\u00e9niques. Recommandations","author":"Anonyme","year":"2014"},{"issue":"21","key":"10.1016\/j.medmal.2017.05.002_bib0370","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1001\/jama.2011.1692","article-title":"Initiation of tumor necrosis factor-\u03b1 antagonists and the risk of hospitalization for infection in patients with autoimmune diseases","volume":"306","author":"Grijalva","year":"2011","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.medmal.2017.05.002_bib0375","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1136\/ard.2011.151043","article-title":"Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?","volume":"70","author":"Strangfeld","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"15","key":"10.1016\/j.medmal.2017.05.002_bib0380","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent","volume":"345","author":"Keane","year":"2001","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.medmal.2017.05.002_bib0385","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.pharmthera.2007.10.001","article-title":"Tumor necrosis factor antagonist mechanisms of action: a comprehensive review","volume":"117","author":"Tracey","year":"2008","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.medmal.2017.05.002_bib0390","series-title":"Recommandations nationales\u00a0: pr\u00e9vention et prise en charge des tuberculoses survenant sous anti-TNF alpha","author":"Anonyme","year":"2005"},{"key":"10.1016\/j.medmal.2017.05.002_bib0395","series-title":"Test de d\u00e9tection de la production d\u2019interf\u00e9ron gamma pour le diagnostic des infections tuberculeuses","author":"Anonyme","year":"2006"},{"key":"10.1016\/j.medmal.2017.05.002_bib0400","series-title":"Tests in vitro de d\u00e9pistage de l\u2019infection tuberculeuse latente par d\u00e9tection de production d\u2019interf\u00e9ron gamma","author":"Anonyme","year":"2015"},{"issue":"6","key":"10.1016\/j.medmal.2017.05.002_bib0405","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1002\/art.21043","article-title":"Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists","volume":"52","author":"Carmona","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.medmal.2017.05.002_bib0410","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1136\/annrheumdis-2011-200690","article-title":"Mycobacterial diseases and antitumour necrosis factor therapy in USA","volume":"72","author":"Winthrop","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.medmal.2017.05.002_bib0415","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1086\/587989","volume":"46","author":"Winthrop","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.medmal.2017.05.002_bib0420","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1378\/chest.12-2820","article-title":"Incidence and risk factors of Legionella pneumophila pneumonia during anti-tumor necrosis factor therapy: a prospective French study","volume":"144","author":"Lanternier","year":"2013","journal-title":"Chest"},{"issue":"21","key":"10.1016\/j.medmal.2017.05.002_bib0425","doi-asserted-by":"crossref","first-page":"6491","DOI":"10.3748\/wjg.v21.i21.6491","article-title":"Nocardia infections among immunomodulated inflammatory bowel disease patients: a review","volume":"21","author":"Abreu","year":"2015","journal-title":"World J Gastroenterol"},{"issue":"2","key":"10.1016\/j.medmal.2017.05.002_bib0430","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1097\/MAJ.0b013e3182883708","article-title":"Risk of nocardial infections with anti-tumor necrosis factor therapy","volume":"346","author":"Ali","year":"2013","journal-title":"Am J Med Sci"},{"issue":"2","key":"10.1016\/j.medmal.2017.05.002_bib0435","doi-asserted-by":"crossref","first-page":"e153","DOI":"10.1016\/j.ijid.2009.03.017","article-title":"Disseminated systemic Nocardia farcinica infection complicating alefacept and infliximab therapy in a patient with severe psoriasis","volume":"14","author":"Al-Tawfiq","year":"2010","journal-title":"Int J Infect Dis"},{"issue":"3","key":"10.1016\/j.medmal.2017.05.002_bib0440","first-page":"539","article-title":"Systemic nocardiosis in a case of rheumatoid arthritis treated with tumor necrosis factor blockers","volume":"35","author":"Wendling","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.medmal.2017.05.002_bib0445","doi-asserted-by":"crossref","DOI":"10.1136\/bcr.11.2008.1262","article-title":"Pulmonary actinomycosis complicating infliximab therapy for Crohn disease","volume":"2009","author":"Cohen","year":"2009","journal-title":"BMJ Case Rep"},{"issue":"5","key":"10.1016\/j.medmal.2017.05.002_bib0450","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1093\/qjmed\/hcn028","article-title":"Pulmonary actinomycosis in a patient with diffuse systemic sclerosis treated with infliximab","volume":"101","author":"Marie","year":"2008","journal-title":"QJM Mon J Assoc Physicians"},{"issue":"6","key":"10.1016\/j.medmal.2017.05.002_bib0455","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1007\/s10620-006-9250-x","article-title":"Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases","volume":"52","author":"Kaur","year":"2007","journal-title":"Dig Dis Sci"},{"issue":"3","key":"10.1016\/j.medmal.2017.05.002_bib0460","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/art.24283","article-title":"Pneumocystis jiroveci pneumonia in patients with rheumatoid arthritis treated with infliximab: a retrospective review and case-control study of 21 patients","volume":"61","author":"Komano","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.medmal.2017.05.002_bib0465","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3109\/s10165-005-0454-2","article-title":"Pneumocystis jiroveci pneumonia in a patient with rheumatoid arthritis as a complication of treatment with infliximab, anti-tumor necrosis factor alpha neutralizing antibody","volume":"16","author":"Mori","year":"2006","journal-title":"Mod Rheumatol"},{"issue":"6","key":"10.1016\/j.medmal.2017.05.002_bib0470","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1097\/01.MIB.0000164002.32735.c2","article-title":"Pneumocystis jiroveci (carinii) pneumonia after initiation of infliximab and azathioprine therapy in a patient with Crohn's disease","volume":"11","author":"Seddik","year":"2005","journal-title":"Inflamm Bowel Dis"},{"issue":"8","key":"10.1016\/j.medmal.2017.05.002_bib0475","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1093\/rheumatology\/41.8.951","article-title":"Pneumocystis carinii pneumonia following a second infusion of infliximab","volume":"41","author":"Tai","year":"2002","journal-title":"Rheumatol Oxf Engl"},{"issue":"5","key":"10.1016\/j.medmal.2017.05.002_bib0480","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1097\/00054725-200409000-00025","article-title":"Pneumocystis carinii pneumonia during maintenance anti-tumor necrosis factor-alpha therapy with infliximab for Crohn's disease","volume":"10","author":"Velayos","year":"2004","journal-title":"Inflamm Bowel Dis"},{"issue":"12","key":"10.1016\/j.medmal.2017.05.002_bib0485","doi-asserted-by":"crossref","first-page":"3826","DOI":"10.1002\/art.27735","article-title":"Trends in hospitalizations for Pneumocystis jiroveci pneumonia among patients with rheumatoid arthritis in the US: 1996-2007","volume":"62","author":"Louie","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.medmal.2017.05.002_bib0490","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/nrrheum.2010.154","article-title":"The Japanese experience with biologic therapies for rheumatoid arthritis","volume":"6","author":"Takeuchi","year":"2010","journal-title":"Nat Rev Rheumatol"},{"issue":"18","key":"10.1016\/j.medmal.2017.05.002_bib0495","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1056\/NEJMc070728","article-title":"Pneumocystis pneumonia associated with infliximab in Japan","volume":"357","author":"Harigai","year":"2007","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.medmal.2017.05.002_bib0500","doi-asserted-by":"crossref","first-page":"R43","DOI":"10.1186\/ar4472","article-title":"Prophylaxis for Pneumocystis pneumonia in patients with rheumatoid arthritis treated with biologics, based on risk factors found in a retrospective study","volume":"16","author":"Katsuyama","year":"2014","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.medmal.2017.05.002_bib0505","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S0002-9343(01)00945-7","article-title":"Reactivation of histoplasmosis after treatment with infliximab","volume":"112","author":"Nakelchik","year":"2002","journal-title":"Am J Med"},{"issue":"9","key":"10.1016\/j.medmal.2017.05.002_bib0510","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1164\/rccm.200206-563OC","article-title":"Histoplasmosis after treatment with anti-tumor necrosis factor-alpha therapy","volume":"167","author":"Wood","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"10.1016\/j.medmal.2017.05.002_bib0515","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1002\/art.10583","article-title":"Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept","volume":"46","author":"Lee","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.medmal.2017.05.002_bib0520","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/ajg.2012.396","article-title":"Histoplasma capsulatum infection in refractory Crohn's disease of the pouch on anti-TNF biological therapy","volume":"108","author":"Lan","year":"2013","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.1016\/j.medmal.2017.05.002_bib0525","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s10792-011-9459-3","article-title":"Acute pulmonary histoplasmosis in a patient with uveitis after infliximab therapy","volume":"31","author":"Lim","year":"2011","journal-title":"Int Ophthalmol"},{"issue":"1","key":"10.1016\/j.medmal.2017.05.002_bib0530","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1086\/648724","article-title":"Recognition, diagnosis, and treatment of histoplasmosis complicating tumor necrosis factor blocker therapy","volume":"50","author":"Hage","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"14","key":"10.1016\/j.medmal.2017.05.002_bib0535","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1056\/NEJM200104053441415","article-title":"Invasive pulmonary aspergillosis associated with infliximab therapy","volume":"344","author":"Warris","year":"2001","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.medmal.2017.05.002_bib0540","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0025-6196(11)60839-2","article-title":"Fungal infections complicating tumor necrosis factor alpha blockade therapy","volume":"83","author":"Tsiodras","year":"2008","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"10.1016\/j.medmal.2017.05.002_bib0545","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1442-9071.2007.01458.x","article-title":"Disseminated mucormycosis and orbital ischaemia in combination immunosuppression with a tumour necrosis factor alpha inhibitor","volume":"35","author":"Singh","year":"2007","journal-title":"Clin Experiment Ophthalmol"},{"issue":"5","key":"10.1016\/j.medmal.2017.05.002_bib0550","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.revmed.2009.04.010","article-title":"Non tuberculous anti-TNF associated opportunistic infections","volume":"31","author":"Marie","year":"2010","journal-title":"Rev Med Int"}],"container-title":["M\u00e9decine et Maladies Infectieuses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0399077X1630172X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0399077X1630172X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T01:14:52Z","timestamp":1759972492000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0399077X1630172X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":55,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S0399077X1630172X"],"URL":"https:\/\/doi.org\/10.1016\/j.medmal.2017.05.002","relation":{},"ISSN":["0399-077X"],"issn-type":[{"value":"0399-077X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Respiratory infections associated with anti-TNF\u03b1 agents","name":"articletitle","label":"Article Title"},{"value":"M\u00e9decine et Maladies Infectieuses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medmal.2017.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}